Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
Status:
Completed
Trial end date:
2018-06-15
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the effect of severe hepatic impairment on the
pharmacokinetics (PK) of telotristat ethyl (TE) ( LP-778902 active moiety, metabolite),
following administration of a single dose of TE 250 mg (1 x 250-mg tablet) compared to
healthy, demographically-matched subjects with normal hepatic function.